Lixte Biotechnology Holdings Inc — Cash Flow (NASDAQ:LIXT)

Financials

Cash from operating activities 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M Cash from investing activities ————— — Cash from financing activities 4.6 M3.9 M5.14 M3.14 M0 6.47 M Free cash flow 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M

뉴스

LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary

LIXTE expands clinical trial for ovarian cancer treatment

스파르탄 캐피털, Lixte의 430만 달러 규모 유상증자 주선

Lixte Biotechnology stock falls after $4.3 million direct offering

Spartan Capital acts as placement agent in Lixte’s $4.3 million offering

릭스테 바이오, 430만 달러 규모 직접 공모 후 주가 하락

Lixte Biotechnology stock falls after $4.3 million direct offering

Lixte Biotechnology raises $4.3 million in registered direct offering

Lixte Biotechnology, 주주총회서 이사 선임 및 주식 계획 수정안 승인

Lixte Biotechnology shareholders approve board nominees and stock plan amendment

Lixte Biotechnology, 영국 Liora 인수 후 주가 하락

Lixte Biotechnology stock falls after acquiring UK-based Liora